Aquestive Therapeutics Inc represents values of innovation, patient-centeredness, and collaboration. The company strives to revolutionize the way patients receive and experience medical treatments by developing and delivering innovative pharmaceutical solutions. Aquestive's corporate philosophy revolves around putting patients first, aiming to improve their quality of life through effective and convenient treatment options. The company's dedication to research and development, along with its focus on building strategic partnerships, enables Aquestive to bring transformative therapies to patients in need. Aquestive Therapeutics Inc's commitment to innovation and patient-centric approach sets it apart in the pharmaceutical industry.

Aquestive Therapeutics Inc primarily operates in the United States.

Some significant milestones that Aquestive Therapeutics Inc has achieved include obtaining FDA approval for their flagship product, Sublocade, a once-monthly injectable treatment for opioid use disorder. In addition, the company has successfully launched other innovative pharmaceutical products, such as Sympazan, an oral film formulation for the treatment of seizures associated with Lennox-Gastaut syndrome. Aquestive Therapeutics Inc has also made progress in developing a diverse pipeline of potential therapies, leveraging their proprietary PharmFilm® technology. Overall, Aquestive Therapeutics Inc has demonstrated a commitment to advancing drug delivery technologies and improving patient outcomes.

Aquestive Therapeutics Inc, a pharmaceutical company founded in 2004, is focused on developing innovative treatments to improve patients' lives. They specialize in developing and commercializing medicines through their proprietary PharmFilm® drug delivery technology. With a strong commitment to transformative therapies, Aquestive Therapeutics has made significant progress in various therapeutic areas, including central nervous system disorders, and oral mucositis. By leveraging their extensive expertise and cutting-edge technology, they aim to address unmet medical needs and enhance patient outcomes. The dedication and unwavering pursuit of excellence have positioned Aquestive Therapeutics as a leader in the pharmaceutical industry.

The main competitors of Aquestive Therapeutics Inc in the market include other pharmaceutical companies that operate in the same therapeutic areas. Some notable competitors are Pfizer Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, and Johnson & Johnson. These companies offer similar products and services, targeting similar patient populations and disease areas. Aquestive Therapeutics Inc focuses on developing innovative treatments and drug delivery solutions, aiming to stand out in the market with its unique approach and industry expertise. However, maintaining a competitive edge is essential in the highly dynamic pharmaceutical industry, where constant innovation and market adaptation play a crucial role.

Aquestive Therapeutics Inc is primarily active in the pharmaceutical industry, specifically focused on developing and commercializing innovative treatments for various medical conditions. They specialize in providing solutions for central nervous system (CNS) disorders and oral films. With their advanced drug delivery technology, Aquestive Therapeutics Inc aims to improve patient outcomes and enhance treatment options.

Aquestive Therapeutics Inc operates as a specialty pharmaceutical company. Its business model is focused on developing and commercializing differentiated products to address unmet medical needs. The company utilizes its proprietary PharmFilm® technology to develop and manufacture pharmaceutical products, including CNS (central nervous system) and RLS (restless legs syndrome) therapies. Aquestive Therapeutics aims to improve patient outcomes and enhance treatment experiences through its innovative drug delivery platforms. By leveraging its expertise in formulation science and regulatory capabilities, the company strives to provide effective and convenient therapeutic options for patients across various medical conditions.

Aquestive Therapeutics의 P/E 비율은 -5.62입니다.

Aquestive Therapeutics의 P/S 비율은 7.83입니다.

Aquestive Therapeutics에 대한 AlleAktien 품질 점수는 4/10입니다.

예상되는 Aquestive Therapeutics 매출은 45.96 백만 USD입니다.

예상되는 Aquestive Therapeutics 이익은 -63.99 백만 USD입니다.

Aquestive Therapeutics Inc is a biopharmaceutical company based in New Jersey that specializes in the development and commercialization of innovative therapies for the treatment of various neurological disorders. Their business strategy is based on a wide range of products and services that provide greater benefits to customers and patients. Here is an overview of the company's business model and products. The business model: Aquestive Therapeutics Inc aims to revolutionize the innovative biopharmaceutical industry through their services and products. Their goal is to develop innovative solutions that help patients improve their quality of life and treat currently incurable diseases. The company has developed a unique platform technology that allows for the oral administration of medications that would normally only be administered through injections or infusions. The products: Aquestive Therapeutics Inc offers a wide range of innovative therapies for the treatment of neurological disorders such as Parkinson's disease, epilepsy, and akathisia. Their products are also intended for the treatment of central nervous system disorders such as stroke and multiple sclerosis. The products include: - Exservan: A chewable medication for the treatment of amyotrophic lateral sclerosis (ALS) and motor neuron disease. - Sympazan: For the treatment of Lennox-Gastaut syndrome, a severe form of epilepsy in children aged two and older. - Subsys: A highly effective fentanyl-containing sublingual spray formulation for the treatment of acute pain in patients who are opioid-dependent due to cancer. - Libervant: An oral spray for the treatment of acute recurring seizures in adults, as well as for the preventive protection against epileptic seizures. - AQST-117 (Riluzole): Developed for the treatment of amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases of the nervous system. - AQST-108: A transdermal medication for the treatment of uncontrolled movements caused by neuroleptics and antiemetics. Aquestive Therapeutics Inc also offers clinical trials to further research and improve their new technology and products. They have conducted extensive research and development activities to address rapidly evolving and dynamic markets for novel treatments. Additionally, the company has formed partnerships with other industry leaders to further accelerate growth. Conclusion: Aquestive Therapeutics Inc has proven that they can operate as one of the fastest-growing biopharmaceutical companies in the industry. With their innovative technology and product portfolio, they have redefined industry standards. Their extensive research and development capabilities give the company a competitive edge in the emerging biopharmaceutical industry. In the future, the company has the opportunity to expand its business through strategic partnerships and collaboration with other leading companies and institutions.

Aquestive Therapeutics은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Aquestive Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Aquestive Therapeutics의 ISIN은 US03843E1047입니다.

Aquestive Therapeutics의 WKN은 A2JQ4G입니다.

Aquestive Therapeutics의 티커는 AQST입니다.

지난 12개월 동안 Aquestive Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Aquestive Therapeutics은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Aquestive Therapeutics의 현재 배당 수익률은 입니다.

Aquestive Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Aquestive Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Aquestive Therapeutics은 '건강' 섹터에 속합니다.

Aquestive Therapeutics의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2024년에 Aquestive Therapeutics는 0 USD를 배당금으로 지급했습니다.

Aquestive Therapeutics의 배당금은 USD에 지급됩니다.